Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics, Inc. Frequently Asked Questions
What is the ticker symbol for Aerovate Therapeutics, Inc.? What does AVTE stand for in stocks?
AVTE is the stock ticker symbol of Aerovate Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Aerovate Therapeutics, Inc. (AVTE)?
As of Mon Dec 02 2024, market cap of Aerovate Therapeutics, Inc. is 76.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of AVTE stock?
You can check AVTE's fair value in chart for subscribers.
Is Aerovate Therapeutics, Inc. a good stock to buy?
The fair value guage provides a quick view whether AVTE is over valued or under valued. Whether Aerovate Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Aerovate Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVTE.